The Business Times
business-time-50
SUBSCRIBERS

Lonza in joint venture to develop biotherapeutic products

google-preferred-sourceAdd BT as a preferred source

Ng Ren Jye

Published Wed, Apr 3, 2019 · 09:50 PM

DeeperDive is a beta AI feature. Refer to full articles for the facts.

Singapore

SWISS biotech company Lonza has entered into an equal joint venture (JV) with Danish bioscience company Chr Hansen Holding to develop live biotherapeutic products (LBP) for pharma and biotech customers.

The phased investment of about 90 million euros (S$136.6 million) will be shared equally between the partners over three years.

lonza

Copyright SPH Media. All rights reserved.

Reuse this contentFeedback

TRENDING NOW

Andrew Lee, chairman of OCBC (right), and group chief executive Tan Teck Long speaking at Thursday's (Apr 16) AGM.

Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman

Allen & Gledhill partner Dinesh Dhillon led the legal team representing Kiri Industries throughout the decade-long dispute.

Why where you park your joint venture matters: Lessons from a US$689 million shareholder dispute

US President Donald Trump (left) with Chinese President Xi Jinping at a bilateral meeting on the sidelines of the Apec summit in Busan last October.

China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result

The yen weakened to a low of 125.33 yen per Singdollar on April 13, before recovering slightly to about 124.91 on April 15.

Singaporeans can now buy record amount of yen per Singdollar

Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More